Use of antibiotics is associated with worse clinical outcomes in patients with cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis

Use of antibiotics is associated with worse clinical outcomes in patients with cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis

Objectives: Observational and experimental studies suggest that the use of antibiotics close to administration of immune checkpoint inhibitors (ICI) can have a negative effect on tumour response and patient survival, due to microbiome dysbiosis and the resultant suppression of host immune response a...

Full description

Bibliographic Details
Main Authors:	Maria Tsikala-Vafea, Neel Belani, Kendra Vieira, Hina Khan, Dimitrios Farmakiotis
Format:	Article
Language:	English
Published:	Elsevier 2021-05-01
Series:	International Journal of Infectious Diseases
Subjects:	Immune checkpoint inhibitors Immunotherapy Microbiome Stewardship
Online Access:	http://www.sciencedirect.com/science/article/pii/S1201971221002812

Similar Items

Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications
by: Daniel Spakowicz, et al.
Published: (2020-05-01)

Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors
by: Konstantinos Melissaropoulos, et al.
Published: (2020-05-01)

Progress of Steroids Effect on Efficacy of Immune Checkpoint Inhibitors
by: Guoqiang PAN, et al.
Published: (2019-12-01)

The Emerging Role of the Gut Microbiome in the Cancer Response to Immune Checkpoint Inhibitors: A Narrative Review
by: Ghada Araji, et al.
Published: (2022-02-01)

Recent Advances in Immune Checkpoint Inhibitor-associated Pneumonitis
by: CHEN Shuangqing, et al.
Published: (2022-10-01)

Calcineurin inhibitors in steroid and anti‐TNF‐alpha refractory immune checkpoint inhibitor colitis
by: Eva Zhang, et al.
Published: (2021-05-01)

Insomnia in patients treated with checkpoint inhibitors for cancer: A meta-analysis
by: Igor Kiss, et al.
Published: (2022-08-01)

Cardiotoxicity of checkpoint inhibitors: focus on immune side effects
by: Yuri I. Buziashvili, et al.
Published: (2024-04-01)

Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors
by: Marion Tonneau, et al.
Published: (2022-12-01)

Clinical Diagnosis and Treatment Recommendations for the Pneumonitis Associated with Immune Checkpoint Inhibitor
by: Hanping WANG, et al.
Published: (2019-10-01)

Skin manifestations associated with checkpoint inhibitors
by: Gianluca Nazzaro, et al.
Published: (2022-06-01)

High pre-treatment neutrophil-to-lymphocyte ratio as a prognostic marker for worse survival in patients with recurrent/metastatic cervical cancer treated with immune checkpoint inhibitors
by: Corinne A. Calo, et al.
Published: (2022-08-01)

Challenges to Successful Implementation of the Immune Checkpoint Inhibitors for Treatment of Glioblastoma
by: Stephanie Sanders, et al.
Published: (2020-04-01)

Updates in the Role of Checkpoint Inhibitor Immunotherapy in Classical Hodgkin’s Lymphoma
by: Shazia Nakhoda, et al.
Published: (2022-06-01)

Research Progress of Efficacy Biomarkers Related to Immune Checkpoint Inhibitors
by: YANG Wenwen, et al.
Published: (2022-05-01)

Immune checkpoint inhibitor‐mediated psoriasis treated with biologics
by: Pei Ming Yeo, et al.
Published: (2023-06-01)

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
by: Pan Shen, et al.
Published: (2021-07-01)

Assessing the role of colonic and other anatomical sites uptake by [18F]FDG‐PET/CT and immune‐inflammatory peripheral blood indexes in patients with advanced non‐small cell lung cancer treated with first‐line immune checkpoint inhibitors
by: Alessio Rizzo, et al.
Published: (2023-08-01)

Immune Checkpoint Inhibitors for Gastrointestinal Malignancies: An Update
by: Kathryn DeCarli, et al.
Published: (2022-08-01)

Update on Immune Checkpoint Inhibitors for Conjunctival Melanoma
by: Ho-Seok Sa, et al.
Published: (2022-08-01)

Immune Checkpoint Inhibitors in Cancer Therapy—How to Overcome Drug Resistance?
by: Yefang Lao, et al.
Published: (2022-07-01)

Patterns of immune-related adverse events in patients treated with immune checkpoint inhibitors: a Brazilian real-world analysis
by: Maria Paula Furtado Santos, et al.
Published: (2022-12-01)

Impact of Antibiotic Therapy and Metabolic Parameters in Non-Small Cell Lung Cancer Patients Receiving Checkpoint Inhibitors
by: Angelo Castello, et al.
Published: (2021-03-01)

Cavitation-Mediated Immunomodulation and Its Use with Checkpoint Inhibitors
by: Matilde Maardalen, et al.
Published: (2023-08-01)

Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
by: Anne Dyhl-Polk, et al.
Published: (2021-06-01)

Immune checkpoint inhibitors in cancer patients with COVID-19
by: Pan Yun, et al.
Published: (2023-07-01)

The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma
by: Nicholas Meti, et al.
Published: (2018-06-01)

Checkpoint Inhibitor-Induced Colitis: An Update
by: Giuseppe Losurdo, et al.
Published: (2023-05-01)

Impact of gut-microbiome altering drugs and fecal microbiota transplant on the efficacy and toxicity of immune checkpoint inhibitors: A systematic review
by: Manish D. Angrish, et al.
Published: (2022-07-01)

Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations
by: Amalia Anastasopoulou, et al.
Published: (2019-09-01)

Checkpoint inhibitors as immunotherapy for fungal infections: Promises, challenges, and unanswered questions
by: Sebastian Wurster, et al.
Published: (2022-10-01)

Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives
by: H. Taghizadeh, et al.
Published: (2019-11-01)

Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity
by: Barbara Seliger
Published: (2019-05-01)

Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature
by: Víctor Albarrán, et al.
Published: (2022-02-01)

Clinical characteristics and therapeutic effects of checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer
by: Li Pang, et al.
Published: (2023-03-01)

Enhancing Checkpoint Inhibitor Therapy in Solid Tissue Cancers: The Role of Diet, the Microbiome & Microbiome-Derived Metabolites
by: Agnieszka Beata Malczewski, et al.
Published: (2021-07-01)

Oncolytic Viruses and Immune Checkpoint Inhibitors: The “Hot” New Power Couple
by: Charlotte Lovatt, et al.
Published: (2023-08-01)

Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients
by: Justin Tong, et al.
Published: (2022-10-01)

Immune checkpoint inhibitor associated ocular hypertension (from presumed trabeculitis)
by: Julia Canestraro, et al.
Published: (2021-09-01)

Impact of antibiotics on the efficacy of immune checkpoint inhibitors in the treatment of primary liver cancer
by: Jia-Ren Wang, et al.
Published: (2022-09-01)